Several reports implicate C5ORF46 as having a pro-tumoral role with possible prognostic value in the development of pancreatic adenocarcinoma (PAAD) (Makler and Narayanan, 2017), colon adenocarcinoma (COAD) (Chen et al., 2021) and stomach adenocarcinoma (STAD) (Cheng et al., 2020), which underline the value of studying C5ORF46 in GI tumors (Makler and Narayanan, 2017; Cheng et al., 2020). The gene discussed is C5orf46; the disease is pancreatic adenocarcinoma.